Evolus, Inc. (EOLS) Key Statistics & Financial Ratios

Evolus, Inc. (EOLS) — Price $7.99 HealthcareDrug Manufacturers - Specialty & Generic — NASDAQ

Latest reported results:

Key statistics dashboard for Evolus, Inc. (EOLS). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.

Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc.

Stock Data

Price$7.99
Market Cap$526M
Enterprise Value$645.8M
Beta1.00
ExchangeNASDAQ
CountryUS

Valuation Multiples

P/E Ratio-15.34
Price / Book-16.95
P/S1.65
EV/EBITDA-63.12
EV/Sales2.04
EV/FCF-32.02
P/FCF-25.94
Earnings Yield-6.52%
FCF Yield-3.83%
Dividend Yield0.00%

Profitability

Gross Margin66.25%
EBIT Margin-5.52%
EBITDA Margin-3.23%
Operating Margin-7.33%
Net Margin-10.85%
Return on Equity123.11%
Return on Assets-13.84%
Return on Invested Capital-15.27%
Return on Capital Employed-15.54%

Financial Health

Current Ratio1.70
Quick Ratio1.28
Cash Ratio0.46
Debt / Equity-5.33
Debt / Assets66.45%
Net Debt / EBITDA-11.69
Interest Coverage-1.43
Piotroski F-Score2
Altman Z-Score-1.94

Per-Share Data

Revenue per share4.80
Book Value per share-0.47
Cash per share0.69
FCF per share-0.31
Tangible Book Value per share-1.48
Dividend per share0.00

Analyst Consensus

Strong Buy0
Buy11
Hold2
Sell0
Strong Sell0
Total analysts13
Avg rating (1-5)0.85

Related companies: AUTL · CBLL · EHAB · KIDS · KMDA · NGNE · QSI

Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic

More sections of EOLS: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events

Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks